2025 North America Artificial Intelligence (Ai) In Drug Discovery Market Revenue Opportunities Report
Description
The 2025 North America Artificial Intelligence (Ai) In Drug Discovery Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Artificial Intelligence (AI) in Drug Discovery Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Artificial Intelligence (AI) in Drug Discovery market in North America are IBM Watson Health, Google DeepMind/Isomorphic Labs, NVIDIA Corporation, and Atomwise Inc. IBM Watson Health employs machine learning and natural language processing to analyze scientific literature and accelerate drug target identification. Google DeepMind, along with its sister company Isomorphic Labs, revolutionized protein structure prediction with AlphaFold, substantially speeding drug candidate identification and has major collaborations with firms like Eli Lilly and Novartis. NVIDIA provides advanced AI hardware and software platforms to enable computational drug discovery workflows, supporting AI model training and drug design at scale. Atomwise uses deep learning for molecule screening and drug candidate prediction, focusing on improving early-stage drug discovery efficiency.
These companies leverage extensive AI technologies such as deep learning, generative models, and natural language processing to reduce drug discovery timelines and costs. Their efforts are supported by significant R&D investments, regulatory facilitation, large biological datasets, and collaborations with pharmaceutical firms. The U.S., which holds nearly half of the North American market share, benefits from this innovation ecosystem, strong pharma presence, and venture capital inputs. This leadership is crucial for addressing growing healthcare challenges like chronic diseases and accelerating personalized therapy development via AI-driven platforms.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Artificial Intelligence (AI) in Drug Discovery Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Artificial Intelligence (AI) in Drug Discovery market in North America are IBM Watson Health, Google DeepMind/Isomorphic Labs, NVIDIA Corporation, and Atomwise Inc. IBM Watson Health employs machine learning and natural language processing to analyze scientific literature and accelerate drug target identification. Google DeepMind, along with its sister company Isomorphic Labs, revolutionized protein structure prediction with AlphaFold, substantially speeding drug candidate identification and has major collaborations with firms like Eli Lilly and Novartis. NVIDIA provides advanced AI hardware and software platforms to enable computational drug discovery workflows, supporting AI model training and drug design at scale. Atomwise uses deep learning for molecule screening and drug candidate prediction, focusing on improving early-stage drug discovery efficiency.
These companies leverage extensive AI technologies such as deep learning, generative models, and natural language processing to reduce drug discovery timelines and costs. Their efforts are supported by significant R&D investments, regulatory facilitation, large biological datasets, and collaborations with pharmaceutical firms. The U.S., which holds nearly half of the North American market share, benefits from this innovation ecosystem, strong pharma presence, and venture capital inputs. This leadership is crucial for addressing growing healthcare challenges like chronic diseases and accelerating personalized therapy development via AI-driven platforms.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
